Re­genxbio touts pos­i­tive mid-stage da­ta for Ab­b­Vie-part­nered vi­sion-loss gene ther­a­py, but no de­tailed plans for piv­otal study

Re­genxbio re­leased pos­i­tive in­ter­im da­ta from its Phase II tri­al of its Ab­b­Vie-part­nered vi­sion-loss gene ther­a­py pro­gram, tout­ing “sta­ble” vi­su­al acu­ity and safe­ty.

The com­pa­ny’s can­di­date, AB­BV-RGX-314, showed “sta­ble” best cor­rect­ed vi­su­al acu­ity, the pri­ma­ry end­point, and cen­tral reti­nal thick­ness at the six-month mark of the 106-pa­tient tri­al in par­tic­i­pants with wet age-re­lat­ed mac­u­lar de­gen­er­a­tion (AMD).

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER